Central Ohio Urology Group

Gahanna, Ohio 43230

7 studies enrolling now · 18 studies all time

What they study most

Bladder Cancer, Bladder Pain Syndrome, Castration-Resistant Prostate Cancer, High-risk Prostate Cancer, Interstitial Cystitis, Low Grade Upper Tract Urothelial Carcinoma, Metastasis From Malignant Tumor of Prostate, Metastatic Castrate-sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma — Recruiting now
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC — Recruiting now
• Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device — Recruiting now
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy — Recruiting now
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Recruiting now
• FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer — Recruiting now
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer — Running, not enrolling
• A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate — Completed
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2) — Completed
• 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome — Stopped early
• Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer — Stopped early